REGISTERED NUMBER: 06630162 (England and Wales)

STRATEGIC REPORT, REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST DECEMBER 2024

FOR

AMPLITY LTD

Page

Company Information

1

Strategic Report

2

Report of the Directors

5

Report of the Independent Auditors

6

Income Statement

9

Other Comprehensive Income

10

Balance Sheet

11

Statement of Changes in Equity

12

Notes to the Financial Statements

13

DIRECTORS:

Ms J Tordoff

Mr M V Watson

REGISTERED OFFICE:

Amplity House

The Vale

Chalfont St. Peter

Gerrards Cross

SL9 9RZ

REGISTERED NUMBER:

06630162 (England and Wales)

AUDITORS:

Richardson Jones

Chartered Accountants &

Registered Auditors

Mercury House

19-21 Chapel Street

Marlow

Buckinghamshire

SL7 3HN

The directors present their strategic report for the year ended 31st December 2024.

The financial results for the year, along with the company's financial position, are detailed in the accompanying financial statements.

The pharmaceutical industry continues to experience positive momentum, driven by several key trends. A growing and aging global population is contributing to a steady rise in unmet medical needs. This, combined with escalating healthcare demands, has spurred the industry to focus on innovation in research and development (R&D) and advanced manufacturing. Efforts to enhance R&D productivity remain a priority, aimed at accelerating the delivery of innovative medicines and vaccines to the market.

Despite this optimism, the industry faces significant challenges. Rising geopolitical uncertainties, the end of a prolonged period of low interest rates, and tightening budgetary constraints are placing sustained pressure on healthcare costs and the broader value chain. In this competitive landscape, Amplity Health continues to face margin pressures while striving to deliver value to its clients.

Amplity Health has already encountered - and may continue to encounter - challenges related to fluctuating global interest rates, currencies and evolving customer behaviors influenced by geopolitical tensions. In response, management has proactively implemented strategies to mitigate these challenges, with a focus on maintaining liquidity, capital resources, and operational performance. While the duration and impact of potential disruptions remain uncertain, the Group's strategic preparedness positions it well to adapt effectively.

Although the Group's operations have minimal environmental impact, the Board acknowledges that robust environmental practices contribute to Amplity Health's reputation and long-term strategic objectives. A strong commitment to sustainability further strengthens the Group's standing as a responsible industry leader, aligning with the growing expectations of its stakeholders.

Principle risks and uncertainties

A - Risks related to employees

The health and well-being of employees is at the heart of the Amplity Health Group's concerns.

The healthcare industry is known for high mobility among its management and talent. In addition, the Amplity Health Group's new competitors, particularly technology companies, may attract profiles that the Amplity Health Group would like to recruit or retain. The loss of some of them could hurt the Amplity Health Group. The Amplity Health Group's success very largely depends on the talent and expertise of its teams as well as on the strength of its relationships with clients.

If the Amplity Health Group were no longer able to actively attract and retain and motivate valuable managers or employees, its prospects, business, financial position and results could be very adversely affected.

B - Risks associated with client portfolios

Significant medical contracts may be terminated on short notice. Moreover, the Amplity Ltd contracts with its clients are under constant threat from rival competitive bids. Finally, with the intensification of corporate consolidation processes at the global level, the risk of losing a laboratory following a merger and/or acquisition has become quite common. All of these factors contribute to the increased risk of a single event having significant consequences.

C - Risks of IT system failures and cybercrime

The digital marketplace is expanding at an unprecedented pace, and the reliance on information technology has never been greater. This dependence entails risks for the Amplity Health Group, such as technical failure, a malicious attack as well as possible internal threats that could lead to an interruption to services, the loss of personal data, the manipulation or disclosure of confidential information. Amplity Health is, however, fully equipped to mitigate these risks through IT protective tools and ongoing training programs designed for all employees.

System failures can be the result of both natural and malicious activities or a simple technical failure. These failures may impact the Amplity Health Group directly or impact one of its partners or suppliers. This can potentially lead to long periods of malfunction and hamper the Amplity Health Group's ability to serve its clients.

Malicious attacks may take the form of denial-of-service attacks, generic or targeted ransomware-type attacks that directly impact the Amplity Health Group's infrastructures or the systems of these suppliers or partners. The number of cyberattacks has been rising sharply since the mid-2010s, and 2024 marks an acceleration and an even more significant professionalization in the context of AI available tools and significant changes in working methods. Each of these has the ability to inhibit normal business operations and even suspend them for periods of time, as well as potentially infecting client deliverables and even their own network environments, thereby causing significant damage.

Finally, insider threats, although normally not malicious, can also be seriously detrimental to normal business operations. Untrained or ignorant staff can unwittingly share sensitive or personal information, or innocently fall prey to the numerous cyber-attacks (phishing, spear phishing, CEO fraud, etc.). The malicious or disgruntled insider, while rare, can also inflict serious reputational or financial damage by purposefully releasing confidential and sensitive information or by committing acts of sabotage resulting in technical failure.

These risks of failure of information systems and cybercrime can have adverse consequences, including in terms of additional costs (remediation costs, contractual penalties owed to clients, regulatory fines) and potential loss of revenue and reputation for the Amplity Health Group, as well as leading to situations in which its legal liability is engaged.

D - Risks related to financial markets

Fluctuations in currency exchange rates could adversely affect our results of operations and financial condition. Because we sell our services in numerous countries, our results of operations and financial condition could be adversely affected by fluctuations in currency exchange rates. We are particularly sensitive to movements in exchange rates between the Euro and the US dollar, the GBP and the Japanese yen.

E - Risks of high interest rates

The Amplity Health Group faces a potential risk associated with high interest rates. Fluctuations in interest rates, particularly significant increases, can have adverse effects on the company's financial position and results of operations. High interest rates can lead to several challenges and negative consequences:

Increased Borrowing Costs: If the Group has outstanding loans or debt instruments with variable interest rates, a rise in interest rates can lead to higher interest expenses. This could result in increased financial burdens, reducing the company's profitability.

Reduced Investment and Expansion: High interest rates may discourage capital investments and expansion initiatives. The cost of financing new projects or acquisitions may become prohibitive, causing the company to delay or scale down its growth plans.

Impact on Client Spending: Elevated interest rates can affect consumer and corporate spending patterns. Clients of the Amplity Health Group mainly biotech's may face higher financing costs, potentially leading to reduced healthcare budgets and expenditures.

Economic Downturn: High interest rates can contribute to economic slowdowns or recessions, which may have a cascading effect on the healthcare industry. Reduced economic activity can lead to decreased demand for healthcare services and solutions.

Currency Exchange Rates: High interest rates in one country can attract foreign capital, leading to currency appreciation. This can impact the company's exposure to fluctuations in currency exchange rates, as mentioned in section D of the report.

To mitigate the risks associated with high interest rates, the Amplity Health Group maintains a prudent financial strategy, which includes monitoring interest rate trends, diversifying its financing sources, and considering hedging strategies when appropriate. Additionally, the company closely monitors economic indicators and adjust its business strategies accordingly to navigate potential challenges posed by changing interest rate environments.

Key performance indicators

Our Corporate Executive Team and Board regularly review key performance indicators (KPIs) to monitor our operational progress. Employees are updated quarterly on performance against these KPIs. Our performance system ties employee bonuses to a relevant subset of these indicators, while the executive remuneration policy is also linked to measures derived from our KPIs. Although all operational KPIs are tracked internally, not all data is published externally due to commercial sensitivities. To report business performance, we utilize a range of adjusted, non-International Financial Reporting Standards (IFRS) metrics, including Adjusted results, free cash flow, and CER growth rates.

Achievements

Amplity Health Group has finalized its rebranding efforts for an official launch in early 2025, introducing a new logo and mantra under the leadership of our new CEO, Chris Baker:

"Pharma At Its Best: Quicker. Better. Nicer.

Your full-service go-to partners, delivering both flexible and specialized medical and commercial services. No matter where you are in the lifecycle of your drug, we scale with ease. Our people-driven tech-enabled DNA fuels everything we do"

Future outlook

Amplity Health Group's transformative efforts were pivotal in overcoming the challenges of 2024. These initiatives have positioned the company to effectively support its clients in an increasingly digitalized environment, ensuring it remains competitive within the industry. However, recently emerged challenges persist, compounded by ongoing uncertainties stemming from global conflicts that continue to affect daily lives. Additionally, the evolving economic landscape, driven by high-interest rates and currency fluctuations, adds further complexity to operations going forward.

ON BEHALF OF THE BOARD:

Mr M V Watson - Director

18th September 2025

The directors present their report with the financial statements of the company for the year ended 31st December 2024.

DIVIDENDS

No dividends will be distributed for the year ended 31st December 2024.

DIRECTORS

Ms J Tordoff has held office during the whole of the period from 1st January 2024 to the date of this report.

Other changes in directors holding office are as follows:

Mr M A Griffith - resigned 5th November 2024

Mr T Janis - resigned 5th November 2024

Mr M V Watson was appointed as a director after 31st December 2024 but prior to the date of this report.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-	select suitable accounting policies and then apply them consistently;

-	make judgements and accounting estimates that are reasonable and prudent;

-	prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS

The auditors, Richardson Jones, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:

Mr M V Watson - Director

18th September 2025

Opinion

We have audited the financial statements of Amplity Ltd (the 'company') for the year ended 31st December 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

-	give a true and fair view of the state of the company's affairs as at 31st December 2024 and of its profit for the year then ended;

-	have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

-	have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

-	the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

-	the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

-	adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

-	the financial statements are not in agreement with the accounting records and returns; or

-	certain disclosures of directors' remuneration specified by law are not made; or

-	we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to Amplity Limited and the healthcare industry in which it operates and considered the risk of acts by the company that were contrary to applicable laws and regulations, such as fraud. We designed audit procedures to respond to the risk, recognizing that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, because fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

We focussed on laws and regulations which could give rise to a material misstatement in the financial statements, including, but not limited to Health and safety regulations and the Companies Act 2006 and UK tax legislation. Our procedures included:

- agreeing the financial statement disclosures to underlying supporting documentation

- enquiries with management

- understanding of management's internal controls designed to prevent and detect irregularities

There are inherent limitations in the audit procedures described above and, the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. As in all our audits, we also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Porter (Senior Statutory Auditor)

for and on behalf of Richardson Jones

Chartered Accountants &

Registered Auditors

Mercury House

19-21 Chapel Street

Marlow

Buckinghamshire

SL7 3HN

18th September 2025

TURNOVER

22,456,299

17,550,068

Cost of sales

3,993,334

3,205,434

GROSS PROFIT

18,462,965

14,344,634

Administrative expenses

17,214,055

14,219,302

OPERATING PROFIT

4

1,248,910

125,332

Interest receivable and similar income

12,609

18,608

PROFIT BEFORE TAXATION

1,261,519

143,940

Tax on profit

5

335,970

37,786

PROFIT FOR THE FINANCIAL YEAR

925,549

106,154

PROFIT FOR THE YEAR

925,549

106,154

OTHER COMPREHENSIVE INCOME

-

-

TOTAL COMPREHENSIVE INCOME FOR THE YEAR

925,549

106,154

FIXED ASSETS

Tangible assets

6

29,873

61,011

CURRENT ASSETS

Debtors

7

11,460,547

11,181,770

Cash at bank

2,308,658

2,157,307

13,769,205

13,339,077

CREDITORS

Amounts falling due within one year

8

10,318,472

10,845,031

NET CURRENT ASSETS

3,450,733

2,494,046

TOTAL ASSETS LESS CURRENT LIABILITIES

3,480,606

2,555,057

CAPITAL AND RESERVES

Called up share capital

10

100

100

Retained earnings

11

3,480,506

2,554,957

SHAREHOLDERS' FUNDS

3,480,606

2,555,057

The financial statements were approved by the Board of Directors and authorised for issue on 18th September 2025 and were signed on its behalf by:

Mr M V Watson - Director

Called up

share

Retained

Total

capital

earnings

equity

£

£

£

Balance at 1st January 2023

100

2,448,803

2,448,903

Changes in equity

Total comprehensive income

-

106,154

106,154

Balance at 31st December 2023

100

2,554,957

2,555,057

Changes in equity

Total comprehensive income

-

925,549

925,549

Balance at 31st December 2024

100

3,480,506

3,480,606

1.	STATUTORY INFORMATION

Amplity Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

The company's ultimate parent company, Amplity Holdco, Inc, has provided written confirmation of its willingness to provide continued financial support to the company as necessary for the foreseeable future, defined as at least 12 months from the date of signing the financial statements for the year ended 31 December 2024.

Amplity Holdco, Inc has prepared group forecasts covering a period of at least 12 months from the date of approval of these financial statements that indicate that the group has sufficient funding and resources available to it to enable the group to meet its forecasted operating expenditure for at least 12 months from the date of signing these financial statements. On this basis, the directors consider it appropriate to prepare these financial statements on a going concern basis.

Financial Reporting Standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

•

the requirements of Section 7 Statement of Cash Flows.

The exemption is claimed as the company is included in the financial statements of the ultimate Parent company, Amplity Holdco, Inc, a company incorporated in Delaware, USA.

Significant judgements and estimates

The preparation of the financial statements requires management to make judgements, estimates and

assumptions that affect reported amounts in the financial statements. Management bases its judgements,

estimates and assumptions on historical experience and on other factors, including expectations of future events, which management believes to be reasonable under the circumstances. Actual results may differ from these estimates.

Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent

liabilities, revenues, and expenses. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision only affects that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Turnover

The company’s arrangements are primarily service contracts that range in duration from a few months to several years. The company recognizes revenue when control of these services is transferred or services are provided to the customer for an amount, referred to as the transaction price, that reflects the consideration to which the company is expected to be entitled in exchange for those goods or services. The company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the company transfers control of the product or service for each performance obligation. Any discounts offered to customers as incentives to induce customers to enter into service agreements are incorporated into the transaction price and recognized ratably over the period when services are performed. The company records revenues net of value added taxes, that are imposed on and concurrent with specific revenue generating transactions.

The Company derives the majority of its revenues in Contract Sales & Medical Solutions from contract sales to the biopharmaceutical industry and broader healthcare market and revenues are recognized over time using a single measure of progress dependent on the performance obligation. Some of the Contract Sales & Medical Solutions contracts contain multiple performance obligations with distinct promises including recruiting, training, operational management and deployment of sales and medical representatives. The company utilizes a single measure of progress for each performance obligation to recognize revenue, which includes deployment of sales representatives based on employee days worked; recruiting based on candidates recruited training and operational management based on usage and delivery of final product. These services meet the over time criterion as the customer consumes the benefit as activities are performed and another party would not need to substantially re-perform the work already completed to satisfy the remaining obligations if the services were migrated to another party.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Short leasehold

-

Straight line over 10 years

Fixtures and fittings

-

20% on cost

Computer equipment

-

33% on cost

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

31.12.24

31.12.23

£

£

Wages and salaries

4,125,548

3,827,124

Social security costs

359,192

350,995

Other pension costs

243,053

240,991

4,727,793

4,419,110

The average number of employees during the year was as follows:

31.12.24

31.12.23

Account management

24

19

Sales/business development

2

3

Production

3

3

Administration

9

14

38

39

31.12.24

31.12.23

£

£

Directors' remuneration

162,402

359,645

Directors' pension contributions to money purchase schemes

7,038

22,585

One of the directors Mr M A Griffith, is based in the USA and remunerated by a fellow group company. This director has shares and share options in the ultimate parent, Amplity Holdco, Inc. The monetary effect of the share based payments are accounted for in the ultimate parent company.

4.	OPERATING PROFIT

The operating profit is stated after charging/(crediting):

31.12.24

31.12.23

£

£

Other operating leases

96,557

93,414

Depreciation - owned assets

55,500

23,470

Auditors' remuneration

16,000

15,000

Foreign exchange differences

(119,213

)

327,255

5.

TAXATION

Analysis of the tax charge

The tax charge on the profit for the year was as follows:

31.12.24

31.12.23

£

£

Current tax:

UK corporation tax

335,970

37,786

Tax on profit

335,970

37,786

Reconciliation of total tax charge included in profit and loss

The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

31.12.24

31.12.23

£

£

Profit before tax

1,261,519

143,940

Profit multiplied by the standard rate of corporation tax in the UK of 25% (2023 - 23.521%)

315,380

33,856

Effects of:

Expenses not deductible for tax purposes

12,805

12,044

Capital allowances in excess of depreciation

-

(8,114

)

Depreciation in excess of capital allowances

7,785

-

Total tax charge

335,970

37,786

6.	TANGIBLE FIXED ASSETS

Fixtures

Short

and

Computer

leasehold

fittings

equipment

Totals

£

£

£

£

COST

At 1st January 2024

23,774

84,863

180,448

289,085

Additions

-

-

24,362

24,362

Disposals

-

(361

)

(76,128

)

(76,489

)

At 31st December 2024

23,774

84,502

128,682

236,958

DEPRECIATION

At 1st January 2024

23,774

34,343

169,957

228,074

Charge for year

-

43,414

12,086

55,500

Eliminated on disposal

-

(361

)

(76,128

)

(76,489

)

At 31st December 2024

23,774

77,396

105,915

207,085

NET BOOK VALUE

At 31st December 2024

-

7,106

22,767

29,873

At 31st December 2023

-

50,520

10,491

61,011

7.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Trade debtors

2,004,709

1,474,348

Amounts owed by group undertakings

8,779,229

9,113,620

Other debtors

369,339

371,075

VAT

-

20,965

Prepayments and accrued income

307,270

201,762

11,460,547

11,181,770

8.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Trade creditors

1,295,638

1,648,479

Amounts owed to group undertakings

4,302,617

4,666,618

Tax

335,970

37,786

Social security and other taxes

98,278

118,813

VAT

9,247

-

Other creditors

101,797

81,840

Deferred income

3,183,468

3,368,986

Accrued expenses

991,457

922,509

10,318,472

10,845,031

9.	LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

31.12.24

31.12.23

£

£

Within one year

-

57,682

The operating lease had expired as of the balance sheet date. Negotiations to renew a new lease contract are continuing at the date of approval of these financial statements.

10.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.12.24

31.12.23

value:

£

£

100

Ordinary

£1

100

100

11.

RESERVES

Retained

earnings

£

At 1st January 2024

2,554,957

Profit for the year

925,549

At 31st December 2024

3,480,506

12.	RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

13.	ULTIMATE CONTROLLING PARTY